• Phase 3 trial results earn Rapid Communication status, underscoring the importance of the ROADS findings in clinical practice, with the trial authors endorsing GammaTile as a new standard-of-care option for newly diagnosed operable brain metastases1
• GammaTile demonstrated 98.7% local tumor control by 12 months, compared to 84.6% for standard-of-care, reducing the risk of surgical bed recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1*
• GammaTile is estimated to reduce the combined risk of tumor recurrence or death by more than 50% compared to standard-of-care (HR: 0.48, 95% CI: 0.30-0.76, p=0.002)1
• The median overall survival for patients who received GammaTile was longer than that of patients who received standard-of-care: median overall survival was 42.5 months compared to 17.6 months with standard-of-care (HR: 0.59, 95% CI: 0.37-0.96, p=0.032)1
• Treatment with GammaTile did not increase the risk of side effects compared to standard-of-care.1

Continue reading→

Former House Majority Leader and global business executive brings decades of public policy and private-sector experience to lead the industry at a pivotal moment for American medical innovationContinue reading→

Phoenix Rises as the Nation’s Premier Bioscience Powerhouse

Under the visionary leadership of Mayor Kate Gallego, Phoenix has transformed into one of the nation’s fastest-rising bioscience hubs. By seamlessly pairing long-term infrastructure investment with forward-thinking economic development strategies, talent cultivation, and dynamic public-private partnerships, Gallego has redefined the city’s economic landscape. In her vision, bioscience is far more than a healthcare initiative—it is a foundational pillar of Phoenix’s future economy, standing proudly alongside semiconductors, engineering, and advanced manufacturing.Continue reading→

True leadership in bioscience education requires building accessible, sustainable pathways that empower students to discover, innovate, and thrive. For over a decade, Dr. Vignesh Subbian has exemplified transformative leadership in research education and training, creating programs and pathways that have opened doors for students across Arizona and beyond. Through his dedicated work at the BIO5 Institute and his shared academic home in biomedical engineering and systems and industrial engineering at the University of Arizona, Dr. Subbian has championed a bold vision that early, active engagement in research is one of the most powerful drivers of student success in biosciences.Continue reading→

Measurement science and regulatory strategy expert to lead global patient-focused endpoint initiatives.Continue reading→

Dr. Sharma, who heads the Research Institute’s Center for Translational Science, is honored by the Arizona Bioindustry AssociationContinue reading→

Regulators, industry leaders, scientists, and those with lived experience converged on how evidence is generated, interpreted, and acted upon across rare diseases, neurology, and pediatrics.Continue reading→

Three established manufacturers now operate as a single organization spanning precision molding, silicone and thermoplastic expertise, and catalog and custom fluid management components. A new unified brand will be introduced in early 2027.Continue reading→

Laboratory expands product development and research capabilities to advance neurodiagnosticsContinue reading→

When discussing the architects of Arizona’s booming innovation economy, state lawmakers and bioscience pioneers alike point to a common champion: Senator Lela Alston. Recognized with the prestigious AZBio Public Service Award, Senator Alston has spent decades in public office laying the institutional, educational, and legislative groundwork that turned central Phoenix into a nationally recognized epicenter for life sciences and medical discovery.Continue reading→